December 04−05, 2024, Berlin, Germany

GA2LEN Global Urticaria Forum (GUF)

December 07−09, 2023, São Paulo, Brazil

GA2LEN UCARE Conference 2023

Poster icon

Effect of remibrutinib on sleep and daily activities in patients with chronic spontaneous urticaria: Results from the phase 3 studies

A.M. Giménez-Arnau, M. Hide, M. Lebwohl, G. Sussman, S. Saini, S. Haemmerle, N. Seko, P. Wang, M. Maurer, El. D. Martzloff
Poster
Poster icon

Safety and efficacy of remibrutinib in Japanese patients with chronic spontaneous urticaria (BISCUIT study interim analysis)

K. Hayama, Y. Chinuki, A. Yagami, A. Kume, T. Sasajima, S. Matsushima, K. Lheritier, S. Haemmerle, M. Hide
Oral Presentation
Poster icon

Physician’s perspective on the burden of CSU for patients and unmet need while treating CSU: Country-wide data from Urticaria Voices

J.A. Bernstein, T.A. Winders, J. McCarthy, P. Saraswat, N.C. Rothe, T. Raftery, K. Weller
Poster
Poster icon

Safety of remibrutinib in patients with chronic spontaneous urticaria: Results from the phase 3 REMIX-1 and REMIX-2 studies

A.M. Giménez-Arnau, P. Staubach, S. Saini, M. Hide, M. Lebwohl, M. Maurer, G. Sussman, S. Haemmerle, K. Lheritier, El. D. Martzloff, A. Zharkov
Poster
Poster icon

CSU disease activity band shift after long-term treatment with remibrutinib in the phase 3 REMIX-1 and REMIX-2 studies

M. Metz, A. M. Giménez-Arnau, P. Staubach, M.F. Puga, K. Kulthanan, X. Gao, K. Lheritier, C.E. Ortmann, N.C. Rothe, S. Haemmerle, A. Fukunaga, M. Hide
Poster
Poster icon

Frequency of angioedema in patients with chronic spontaneous urticaria: Report from the Urticaria Voices study

J.A. Bernstein, T. A. Winders, M.M. Balp, P. Saraswat, J. McCarthy, T. Raftery, M. Kuruvilla, K. Weller
Poster
Poster icon

No clinically meaningful impact of remibrutinib on immunoglobulin levels or infections in chronic spontaneous urticaria

G. Sussman, M. Palumbo, S. Gogate, A. Fukunaga, S.F. Thomsen, M. Maurer, A. Burciu, P. Wang
Poster
Poster icon

Impact of remibrutinib on Dermatology-Related Quality of Life (DLQI) in patients with chronic spontaneous urticaria in the phase 3 REMIX-1 and REMIX-2 studies

M. Metz, J. Reed, S. Saini, R. Szalewski, M. Lebwohl, M. Maurer, G. Sussman, S. Haemmerle, N. Seko, P. Wang, C. Field, M.J. Palumbo
Poster
Poster icon

Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies

A.M. Giménez-Arnau, M. Metz, M. Hide, V. Jain, A. Khemis, M. Lebwohl, M. Palumbo, S. Saini, E. Şavk, G. Sussman, R. Szalewski, I.W. Herniczek, H. Windom, B. Yang, S. Haemmerle, K. Lheritier, P.G.P. Machado, El-D. Martzloff, N. Seko, P. Wang, M. Maurer, A. Zharkov
Poster
Poster icon

REMIX-1/-2: Early symptom improvements with remibrutinib in chronic spontaneous urticaria from week 1

S. Saini, R. Szalewski, X. Gao, S. Altrichter, S. Haemmerle, N. Seko, M. Hide
Poster
Poster icon

Efficacy of remibrutinib on patients with chronic spontaneous urticaria with or without prior exposure to biologics in the phase 3 REMIX-1 and REMIX-2 studies

S. Saini, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, M. Maurer, M. Metz, G. Mosnaim, G. Sussman, S. Haemmerle, K. Lheritier, El-D. Martzloff, N. Seko, P. Wang, S. Gogate
Poster
Poster icon

Effect of remibrutinib treatment on disease activity in chronic spontaneous urticaria: Data from the phase 3 REMIX-1 and REMIX-2 studies

S. Saini, M. Maurer, F. Berard, J. Reed, S. Altrichter, C.Yu. Chu, B. Suryawanshi, C.E. Ortmann, N.C. Rothe, S. Haemmerle, J. Kern
Poster
Poster icon

Worldwide experiences and unmet needs of patients with chronic spontaneous urticaria and treating physicians: The Urticaria Voices study

Tonya A. Winders, Jonathan A. Bernstein, Maria-Magdalena Balp, Jessica McCarthy, Pedro Laires, Pallavi Saraswat, Tara Raftery, Karsten Weller
Poster
Novartis logo
Cookie Settings
© Copyright 2025 Novartis Pharma AG